<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34044752</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>A practical method for evaluating the <i>in vivo</i> efficacy of EVA-71 vaccine using a hSCARB2 knock-in mouse model.</ArticleTitle><Pagination><StartPage>1180</StartPage><EndPage>1190</EndPage><MedlinePgn>1180-1190</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2021.1934558</ELocationID><Abstract><AbstractText>Hand-foot-and-mouth disease is a contagious disease common among children under 5 years old worldwide. It is caused by strains of enterovirus, especially EV-A71, which can lead to severe disease. Vaccines are the only way to fight this disease. Accordingly, it is necessary to establish an efficient and accurate methodology to evaluate vaccine efficacy <i>in vivo</i>. Here, we established a practical method using a hSCARB2 knock-in mouse model, which was susceptible to EV-A71 infection at 5-6 weeks of age, to directly determine the efficacy of vaccines. Unlike traditional approaches, one-week-old hSCARB2 mice were immunized twice with a licensed vaccine, with an interval of a week. The titre of antibodies was measured after 1 week. Mice at 4 weeks of age were challenged with EV-A71 intraperitoneally and intracranially, respectively. The unimmunized hSCARB2 mice displayed systemic clinical symptoms and succumbed to the disease at a rate of approximately 50%. High viral loads were detected in the lungs, brain, and muscles, accompanied by clear pathological changes. The expression of IL-1&#x3b2;, IL-13, IL-17, and TNF-&#x3b1; was significantly upregulated. By contrast, the immunized group was practically normal and indistinguishable from the control mice. These results indicate that the hSCARB2 knock-in mouse is susceptible to infection in adulthood, and the <i>in vivo</i> efficacy of EV-A71 vaccine could be directly evaluated in this mouse model. The method developed here may be used in the development of new vaccines against HFMD or quality control of licensed vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5624-558X</Identifier><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, Institute for Food and Drug Safety Evaluation, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yanwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, Institute for Food and Drug Safety Evaluation, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Susu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jianhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chunnan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weijin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Youchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Changfa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5556-2025</Identifier><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051907">Lysosomal Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074299">SCARB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051907" MajorTopicYN="N">Lysosomal Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">hSCARB2 knock-in mouse model</Keyword><Keyword MajorTopicYN="N">in vivo vaccine efficacy</Keyword><Keyword MajorTopicYN="N">practical evaluation method</Keyword><Keyword MajorTopicYN="N">quality control</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34044752</ArticleId><ArticleId IdType="pmc">PMC8205003</ArticleId><ArticleId IdType="doi">10.1080/22221751.2021.1934558</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander JP, Baden L, Anderson PLJ.. Enterovirus 71 infections and neurologic disease-United States, 1977-1991. J Infect Dis. 1994;169(4):905&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">8133108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM, Guixia Y, Smith LJ, et al. . A mouse model of paralytic myelitis caused by enterovirus D68. PLoS Pathog. 2017;13(2):e1006199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322875</ArticleId><ArticleId IdType="pubmed">28231269</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, Masaki A, Hasegawa S, et al. . Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis. 2009;62(4):254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">19628900</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MH. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines. Expert Rev Vaccines. 2015;14(3):337&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">25536888</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. 2008;7(10):868&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, et al. . Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, Gasparrini A, Huang J, et al. . The exposure-response relationship between temperature and childhood hand, foot and mouth disease: a multicity study from mainland China. Environ Int. 2017;100:102&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">28069250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Liu F, Liao Q, et al. . Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Eurosurveillance. 2017;22(50):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi CZ, Zeng QK, Yong JB, et al. . Epidemiological research on hand, foot, and mouth disease in Mainland China. Viruses. 2015;7(12):6400&#x2013;6411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690870</ArticleId><ArticleId IdType="pubmed">26690202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pin Y, Linlin B, Lili X, et al. . Neurotropism in vitro and mouse models of severe and mild infection with clinical strains of enterovirus 71. Viruses. 2017;9(11):351. doi:10.3390/v9110351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9110351</ArticleId><ArticleId IdType="pmc">PMC5707558</ArticleId><ArticleId IdType="pubmed">29156632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra Y, Tubau F, Gonz&#xe1;lez-D&#xed;az A, et al. . Assessment of trimethoprim-sulfamethoxazole susceptibility testing methods for fastidious Haemophilus spp. Clin Microbiol Infect. 2019;26(7):944.e1&#x2013;944.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31811916</ArticleId></ArticleIdList></Reference><Reference><Citation>Eun J, Yun J, Jeong H, et al. . Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, et al. . Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine. 2012;30(22):3295&#x2013;3303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Li RC, Liu LD, Mo ZJ, et al. . An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, et al. . Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, et al. . EV71: an emerging infectious disease vaccine target in the far east? Vaccine. 2010;28(20):3516&#x2013;3521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Longding L, Ying Z, Jingjing W, et al. . Study of the integrated immune response induced by an inactivated EV71 vaccine. Plos One. 2013;8(1):e54451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Cao Q, Yang W, et al. . Interchangeability of two enterovirus 71 inactivated vaccines in Chinese children: a phase IV, open-label, and randomized controlled trial. Vaccine. 2020;38(12):2671&#x2013;2677.</Citation><ArticleIdList><ArticleId IdType="pubmed">32067817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang L, Liao Y, et al. . Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children. Vaccine. 2015;33(46):6290&#x2013;6297.</Citation><ArticleIdList><ArticleId IdType="pubmed">26419198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Yu CK.. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci. 2014;21(1):31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013435</ArticleId><ArticleId IdType="pubmed">24742252</ArticleId></ArticleIdList></Reference><Reference><Citation>Imura A, Sudaka Y, Takashino A, et al. . Development of an enterovirus 71 vaccine efficacy test using human scavenger receptor B2 transgenic mice. J Virol. 2020;94(6):e01921-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158731</ArticleId><ArticleId IdType="pubmed">31896594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, et al. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice; 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cui W, Liu L, et al. . Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest. 2011;91(9):1337&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, Li P, Song N, et al. . Genomic and immunologic factors associated with viral pathogenesis in a lethal EV71 infected neonatal mouse model. Mol Med Rep. 2016;13(5):4183&#x2013;4190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838153</ArticleId><ArticleId IdType="pubmed">27035332</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Li YS, Chiou CC, et al. . Expression of caspid protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection. J Med Virol. 2000;61(2):228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">10797379</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Chow VTK, et al. . Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microb Infect. 2007;9(11):1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Jiang Z, Ma Q, et al. . Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. J Thorac Dis. 2016;8(5):803&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842828</ArticleId><ArticleId IdType="pubmed">27162653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, et al. . Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci. 2000;7:523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, et al. . Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20(5):895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Gao F, Wang X, et al. . Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris. Human Vacc Immunother. 2019;16(7):1602&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482752</ArticleId><ArticleId IdType="pubmed">31403352</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der SSMG, Sachs N, Koekkoek SM, et al. . Enterovirus 71 infection of human airway organoids reveals VP1-145 as a viral infectivity determinant. Emerg Microbes Infect. 2018;7(1):84: 1&#x2013;9. doi:10.1038/s41426-018-0077-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0077-2</ArticleId><ArticleId IdType="pmc">PMC5943241</ArticleId><ArticleId IdType="pubmed">29743570</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiya Y, Ken F, Satoshi K.. Scavenger receptor B2 as a receptor for hand, foot, and mouth disease and severe neurological diseases. Front Microbiol. 2012;3(32):1&#x2013;6. doi:10.3389/fmicb.2012.00032</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00032</ArticleId><ArticleId IdType="pmc">PMC3277273</ArticleId><ArticleId IdType="pubmed">22363322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, et al. . Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15(7):798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, et al. . Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol. 2013;87(6):3335&#x2013;3347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhang L, Yang P, et al. . The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection. Protn Cell. 2017;8(008):590&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546930</ArticleId><ArticleId IdType="pubmed">28447294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Koike S.. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J Virol. 2011;85(10):4937&#x2013;4946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126200</ArticleId><ArticleId IdType="pubmed">21389126</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, et al. . Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA. 2013;110(36):14753&#x2013;14758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, et al. . Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8(2):e57591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou AT, Wu SY, Liao CC, et al. . A new animal model containing human SCARB2 and lacking stat-1 is highly susceptible to EV71. Sci Rep. 2016;6(1):31151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4976353</ArticleId><ArticleId IdType="pubmed">27499235</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu YZ, Qiang L, Xi W, et al. . A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice. Vaccine. 2016;34(24):2729&#x2013;2736.</Citation><ArticleIdList><ArticleId IdType="pubmed">27102822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Chen N, Zhou S, et al. . Severity of enterovirus A71 infection in a human SCARB2 knock-in mouse model is dependent on infectious strain and route. Emerg Microbes Infect. 2018;7(1):205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6281673</ArticleId><ArticleId IdType="pubmed">30518755</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia R, Xiang LI, Xingui T.. Seroepidemiology investigation of EV71 neutralizing activity in healthy blood donors in Guangzhou. Chin J Blood Trans. 2010;23:197&#x2013;200.</Citation></Reference><Reference><Citation>Shimizu H, Utama A, Onnimala N, et al. . Molecular epidemiology of enterovirus 71 infection in the Western Pacific region. Pediatr Int. 2010;46(2):231&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Solomon T, et al. . Clinical studies on EV71 neurological disease. Int J Infect Dis. 2008;12(1):e13. doi:10.1016/j.ijid.2008.05.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2008.05.075</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan CB, Yeo DH, et al. . A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2011;86(4):2121&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YX, Zhao H, Ca ORY, et al. . Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice. Virol J. 2014;11(1):79,1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030048</ArticleId><ArticleId IdType="pubmed">24885030</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo C, Yang J, Lei L, et al. . Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. Vaccine. 2017;35(52):7322&#x2013;7330.</Citation><ArticleIdList><ArticleId IdType="pubmed">29129453</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Li J, Hu Y, et al. . Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice. Carbohydr Polym. 2010;82(3):680&#x2013;686.</Citation></Reference><Reference><Citation>Laura L, Culley FJ.. Innate immunity to respiratory infection in early life. Front Immunol. 2017;8:1570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5694434</ArticleId><ArticleId IdType="pubmed">29184555</ArticleId></ArticleIdList></Reference><Reference><Citation>Taleb SA, Al TAA, Khalid AA, et al. . Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol. 2018;37:1817&#x2013;1827.</Citation><ArticleIdList><ArticleId IdType="pubmed">29876771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiangwei K, Qiang C, Rong D, et al. . Clinical values of cortisol, &#x3b2;-endorphin and some cytokines in children with HFMD. Int J Lab Med. 2014;35(12):1547&#x2013;1549.</Citation></Reference><Reference><Citation>Isabel Y, Laa PC, et al. . T cell immunity to enterovirus 71 infection In humans and implications For vaccine development. Int J Med Sci. 2018;15(11):1143&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097258</ArticleId><ArticleId IdType="pubmed">30123051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SY, Xu MY, Xu HM, et al. . Immunologic characterization of cytokine responses to enterovirus 71 and coxsackievirus A16 infection in children. Medicine (Baltimore). 2015;94(27):e1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504596</ArticleId><ArticleId IdType="pubmed">26166120</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>